ClinicalTrials.gg
CompletedNCT03341741CotoCFIIUpdated Nov 14, 2017

Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients

A Phase 3 interventional study of Tobramycin Powder and Colistin in Cystic Fibrosis With Pulmonary Manifestations, sponsored by University Hospital Tuebingen. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by University Hospital Tuebingen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Mar 2014, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

To assess whether the inhalative combination of Tobramycin/Colistin is more effective in reducing Pseudomonas colony forming units (CFUs) and improvement of lung function than Colistin in mono-therapy.

Read the detailed description

Cystic fibrosis (CF), the most common autosomal recessive disorder in Western countries, is caused by mutations of the cystic fibrosis transmembrane conductance regulator molecule (CFTR) and affects approximately 40.000 patients in Europe. The majority of CF patients develop chronic pulmonary infections with Pseudomonas aeruginosa. These are normally treated with single antibiotics, administered orally, intravenously or inhalatively. Once the infection becomes chronic, eradication of the pathogen is not any more possible due to biofilm formation of the pathogen and increasing resistance. However, inhalative antibiotic combination therapy might be more efficient than single antibiotic therapy in chronically infected CF patients. This notion is supported by previous in vitro and animal studies using Tobramycin/Colistin combination therapy. Importantly, a pilot study in five CF patients who inhaled consecutively Colistin and Tobramycin solutions for 4 week, revealed a decrease of log10 2.52 ± 2.5 cfu of P. aeruginosa in sputum specimens during the course of the treatment compared to baseline values (p=0.027). The treatment was shown to be safe and well tolerated. However, forced expiratory volume in 1 sec (FEV1) did not differ significantly.

Taking advantage of the new development of dry powder inhalation (DPI) antibiotics, specifically TOBI© Podhaler, a larger randomised trial has been performed in which the combined TOBI© Podhaler and Colistin treatment is compared to the monotherapy with Colistin.

02

Conditions studied

  • Cystic Fibrosis With Pulmonary Manifestations

Browse trials for

Keywords

  • chronic pulmonary infection
03

In context

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

This study's enrollment of 26 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 491 studies on the registry; 109 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cystic Fibrosis is verified;
  2. Patient is 12 years or older;
  3. is higher than 25% and lower than 100%;
  4. The patients' lung is colonised with P. aeruginosa chronically (≥6 months);
  5. P. aeruginosa must be sensitive for Tobramycin or Colistin;
  6. Pretreated with Colistin >2 months;
  7. Last i.v. antibiotic treatment ≥2 weeks;
  8. is given by patients/legal representatives

Exclusion criteria

Exclusion Criteria:

  1. Clinical deterioration is present (exacerbation symptoms);
  2. Last Tobramycin inhalation treatment ≤ 2 weeks;
  3. Renal dysfunction (creatinine \<1.5 fold of normal, (GFR) \<80%) at baseline
  4. auditoria or vestibular dysfunction, hearing loss
  5. Intolerances against Tobramycin, Colistin or Polymyxin B
  6. Myasthenia gravis
  7. Porphyria
  8. Pregnancy and nursing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Tobramycin powder / Colistin

    TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days

    Drug: Tobramycin Powder · Drug: Colistin

  • Active comparator
    Colistin

    Colistin solution 2 x daily 1 Mega continuously for at least 30 days

    Drug: Colistin

Interventions

  • TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);

    Also known as: TOBI®Podhaler

  • Colistin solution 2 x daily 1 Mega continuously

    Also known as: Colistin solution

06

What researchers measure

Primary outcomes

  1. Amount of P. aeruginosa in sputum

    The primary endpoint will be the difference of P. aeruginosa cfu/ml in sputum with combined therapy with Tobramycin/Colistin compared to colistin mono-therapy. The analysis will be adjusted for baseline values of each cycle and parametric (paired t-Test) or non-parametric (sign test) methods will be used as appropriate.

    Time frame: 30 days

Secondary outcomes

  1. Course of P.aeruginosa amount in sputum

    Course of P. aeruginosa in sputum measured as cfu/ml during the study

    Time frame: 112 days

  2. Course of forced vital capacity (FVC) absolute amount

    Course of FVC absolute in litres during the study

    Time frame: 112 days

  3. Course of FVC relative amount

    Course of FVC relative (percent of expected amount for given body height and gender) during the study

    Time frame: 112 days

  4. Course of FEV1 absolute amount

    Course of FEV1 absolute in litres during the study

    Time frame: 112 days

  5. Course of FEV1 relative amount

    Course of FEV1 relative (percent of expected amount for given body height and gender) during the study

    Time frame: 112 days

  6. Course of MEF25-75 absolute amount

    Course of MEF25-75 absolute in litres during the study

    Time frame: 112 days

  7. Course of MEF25-75 relative amount

    Course of MEF25-75 relative (percent of expected amount for given body height and gender) during the study

    Time frame: 112 days

  8. Course of proinflammatory cytokine IL1ß amount

    Course of proinflammatory cytokine IL1ß amount in sputum \[pg/ml\] during the study

    Time frame: 112 days

  9. Course of proinflammatory cytokine IL6 amount

    Course of proinflammatory cytokine IL6 amount in sputum \[pg/ml\] during the study

    Time frame: 112 days

  10. Course of proinflammatory cytokine IL8 amount

    Course of proinflammatory cytokine IL8 amount in sputum \[pg/ml\] during the study

    Time frame: 112 days

  11. Course of antiinflammatory cytokine IL10 amount

    Course of antiinflammatory cytokine IL10 amount in sputum \[pg/ml\] during the study

    Time frame: 112 days

  12. Course of proinflammatory cytokine TNFa amount

    Course of proinflammatory cytokine TNFa amount in sputum \[pg/ml\] during the study

    Time frame: 112 days

  13. Course of proinflammatory cytokine GM-CSF amount

    Course of proinflammatory cytokine GM-CSF amount in sputum \[pg/ml\] during the study

    Time frame: 112 days

  14. Course of DNA amount in sputum

    Course of DNA amount {pg/ml\] in sputum during the study

    Time frame: 112 days

  15. Course of leukocyte amount in sputum

    Course of leukocyte amount \[pg/ml\] in sputum during the study

    Time frame: 112 days

  16. Exacerbation

    Number of exacerbations during the study

    Time frame: 112 days

  17. Antibiotics

    Use of antibiotics during the study

    Time frame: 112 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Dec 2015, 21 months.

Of 67 phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 39. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2017
First posted
Nov 14, 2017
StartActual
Mar 11, 2014
Primary completionActual
Dec 19, 2015
CompletionActual
Nov 25, 2016
Last update
Nov 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03341741
Responsible party
Sponsor
First posted
Nov 14, 2017
Start date
Mar 11, 2014
Primary completion
Dec 19, 2015
Completion
Nov 25, 2016
Last update
Nov 14, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion